DrugPatentWatch Database Preview
GANZYK-RTU Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Which patents cover Ganzyk-rtu, and what generic alternatives are available?
Ganzyk-rtu is a drug marketed by Exela Pharma Scs Llc and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in GANZYK-RTU is ganciclovir . There are twenty-seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ganciclovir profile page.
US ANDA Litigation and Generic Entry Outlook for Ganzyk-rtu
Ganzyk-rtu was eligible for patent challenges on December 31st, 1968.
Summary for GANZYK-RTU
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | GANZYK-RTU at DailyMed |
Pharmacology for GANZYK-RTU
| Drug Class | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor Nucleoside Analog Antiviral |
| Mechanism of Action | DNA Polymerase Inhibitors |
US Patents and Regulatory Information for GANZYK-RTU
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exela Pharma Scs Llc | GANZYK-RTU | ganciclovir | SOLUTION;INTRAVENOUS | 209347-001 | Feb 17, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
